Objective: To evaluate the efficacy and safety of Alutard standardized mites allergens vaccine in the treatment of allergic asthma in children. Methods: Self-control method was used

subcutaneous injection of specific immune vaccine (Alutard) was given to 125 children with dust mite allergic asthma. The asthma symptoms

drug medication scores and incidence of immune-related adverse drug reactions were recorded and calculated to evaluate the treatment safety before and after treatment. Results: The asthma symptoms in 125 children were significantly improved

and drug medication scores were significantly reduced after desensitization treatment of one year. Totally 80.0% (100/125) of asthma in children were accompanied by allergic rhinitis

and there was a significant improvement in rhinitis symptoms after desensitization treatment of one year. As the symptoms of asthma had been improved significantly in 23.2% of the children

the drug combination was automatically stopped at the 26th weekend of treatment

and the asthma recurrence rate was 10.3% (3/29) at the 52nd weekend of follow-up. One hundred and twenty-five children received a total of 2

676 immunotherapy injections. There were 100 local adverse drug reactions in 43 children

and the incidence of local adverse drug reactions was 3.7% (100/2

676). There were 23 systemic adverse drug reactions in 14 children

with the incidence of 0.9%(23/2

676)

and no fatal systemic adverse drug reactions were observed. Conclusion: Desensitization treatment with standardized allergens is the safe and effective treatment under standardized operation.